Conformis - CFMS Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CFMS shares.
View CFMS analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Conformis' shares. Their CFMS share price forecasts range from $1.00 to $8.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price.
View analysts price targets for CFMS or view top-rated stocks among Wall Street analysts.

Conformis' stock was trading at $0.7610 on January 1st, 2022. Since then, CFMS shares have increased by 267.9% and is now trading at $2.80.
View the best growth stocks for 2022 here.

Conformis saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 71,800 shares, a drop of 73.5% from the October 31st total of 271,100 shares. Based on an average daily trading volume, of 89,700 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the shares of the company are short sold.
View Conformis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our CFMS earnings forecast.

Conformis, Inc. (NASDAQ:CFMS) posted its quarterly earnings data on Wednesday, November, 2nd. The medical instruments supplier reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The medical instruments supplier earned $13.78 million during the quarter, compared to analysts' expectations of $13.89 million. Conformis had a negative trailing twelve-month return on equity of 78.14% and a negative net margin of 104.46%.

Conformis issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.00 million-$14.00 million, compared to the consensus revenue estimate of $15.99 million.

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

Conformis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (98.28%), Renaissance Technologies LLC (63.37%), Granite Point Capital Management L.P. (0.82%), MYDA Advisors LLC (0.37%) and Bank of New York Mellon Corp (4.89%). Insiders that own company stock include Erin Henry, J Brent Alldredge, Kenneth P Fallon III, Mark A Augusti, Mark A Augusti and Robert S Howe.
View institutional ownership trends.

Shares of CFMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CFMS stock can currently be purchased for approximately $2.80.

Conformis (NASDAQ:CFMS) has a market capitalization of $21.05 million and generates $99.86 million in revenue each year. The medical instruments supplier earns $-2,410,000.00 in net income (profit) each year or ($8.75) on an earnings per share basis.

The company employs 310 workers across the globe.

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The official website for the company is www.conformis.com. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at ir@conformis.com, or via fax at 781-345-0147.